The inhibition of EphA2 couldbe advantageous in cancer therapy whenever EphA2 activation mediates tumorprogression as previously demonstrated on mammary tumors and melanoma cells [28], [29].Currently, many strategies to block EphA2 signaling have been explored. The gene discussed is EPHA2; the disease is breast cancer.